Artificial Intelligence Platform Helps Find Combination Drug Treatments for COVID-19
|
By HospiMedica International staff writers Posted on 08 Apr 2020 |
|
Image: AI powered drug discovery (Photo courtesy of Healx)
Healx (Cambridge, UK), an AI-powered biotech company specializing in rare diseases, is using its AI platform to develop drug combinations from approved drugs to contribute towards global efforts to find treatments for COVID-19. This focus on combination therapies, where two or more drugs simultaneously target different aspects of the disease pathology, has the potential to ensure a more effective treatment.
Healx is an AI-powered and patient-inspired technology company, accelerating the discovery and development of rare disease treatments. Many patients in this demographic suffer from pre-existing conditions relating to the heart and respiratory system which have been associated with the highest mortality rates amongst COVID-19 patients. Given this increased vulnerability to COVID-19, and the acute need for treatments, Healx is dedicating its time, knowledge, experience and technology towards fighting the viral infection. The treatments Healx intends to develop are also likely to have wide use amongst other patients identified as vulnerable.
Healx’s AI platform, Healnet, integrates and analyzes biomedical data from multiple sources to predict those combination therapies that are most likely to succeed in the clinic. The company’s AI drug discovery platform leverages public and proprietary biomedical data and features the world’s leading knowledge graph for rare diseases. Healnet is widely regarded as the world’s most efficient and comprehensive AI platform for rare diseases. Combination therapy candidates will be available in May for preclinical testing.
“The recent spread of COVID-19 is risking the lives of millions of rare disease patients across the world. The company’s AI technology is perfectly positioned to support the efforts to find treatments for COVID-19. Healx’s data-driven AI platform is able to predict, within weeks, which known drugs can be repurposed to treat other conditions such as COVID-19,” said Dr. David Brown, Healx Chairman and Co-founder. “This approach significantly shortens discovery-to-clinic timelines. Our AI is able to combine 2-3 existing drugs to formulate the most effective treatment. This approach ensures that any potential treatments we identify can be used by clinicians to help patients very quickly.”
Related Links:
Healx
Healx is an AI-powered and patient-inspired technology company, accelerating the discovery and development of rare disease treatments. Many patients in this demographic suffer from pre-existing conditions relating to the heart and respiratory system which have been associated with the highest mortality rates amongst COVID-19 patients. Given this increased vulnerability to COVID-19, and the acute need for treatments, Healx is dedicating its time, knowledge, experience and technology towards fighting the viral infection. The treatments Healx intends to develop are also likely to have wide use amongst other patients identified as vulnerable.
Healx’s AI platform, Healnet, integrates and analyzes biomedical data from multiple sources to predict those combination therapies that are most likely to succeed in the clinic. The company’s AI drug discovery platform leverages public and proprietary biomedical data and features the world’s leading knowledge graph for rare diseases. Healnet is widely regarded as the world’s most efficient and comprehensive AI platform for rare diseases. Combination therapy candidates will be available in May for preclinical testing.
“The recent spread of COVID-19 is risking the lives of millions of rare disease patients across the world. The company’s AI technology is perfectly positioned to support the efforts to find treatments for COVID-19. Healx’s data-driven AI platform is able to predict, within weeks, which known drugs can be repurposed to treat other conditions such as COVID-19,” said Dr. David Brown, Healx Chairman and Co-founder. “This approach significantly shortens discovery-to-clinic timelines. Our AI is able to combine 2-3 existing drugs to formulate the most effective treatment. This approach ensures that any potential treatments we identify can be used by clinicians to help patients very quickly.”
Related Links:
Healx
New
Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Gold Member
12-Channel ECG
CM1200B
New
Syringe Pump
SP50 Series
New
Pediatric Mask
Respire SOFT
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans
Channels
Artificial Intelligence
view channel
AI Model Uses Eye Imaging to Identify Risk of Major Systemic Diseases
Early detection of systemic disease risk remains a persistent challenge in population health screening. Cardiometabolic conditions such as diabetes, heart disease, and stroke often progress without symptoms... Read more
AI Platform Interprets Real-Time Wearable Data for Parkinson’s Management
Parkinson’s disease presents fluctuating motor and non-motor symptoms that complicate day-to-day self-management and clinical decision-making. Care teams require timely, longitudinal insight into medication... Read more
Critical Care
view channel
Blood-Filtering Device May Prolong Pregnancy in Severe Early Preeclampsia
Preeclampsia is a hypertensive disorder of pregnancy that can progress rapidly and threaten the lives of both mother and fetus. In its severe early form, often before 34 weeks’ gestation, clinicians frequently... Read more
AI Tool Predicts In-Hospital Cardiac Arrest Minutes in Advance
Sudden cardiac arrest, the abrupt loss of heart function, often arises without clear warning in hospitalized patients. Clinicians must sift through faint signals from routine monitoring while limiting... Read more
Surgical Techniques
view channel
Noninvasive Cardiac Radiotherapy Reduces Ventricular Tachycardia Events
Life-threatening ventricular tachycardia is a rapid heart rhythm originating in the ventricles that can trigger sudden cardiac death. Patients who continue to have ventricular tachycardia despite guideline-based... Read more
Augmented Reality System for Knee Replacement Receives FDA Clearance
Total knee arthroplasty requires precise implant alignment while maintaining efficient, reproducible workflows. Many operating rooms, particularly ambulatory surgical centers, need guidance technologies... Read more
Patient Care
view channel
Wearable Sleep Data Predict Adherence to Pulmonary Rehabilitation
Chronic obstructive pulmonary disease (COPD) is a long-term lung disorder that makes breathing difficult and often disturbs sleep, reducing energy for daily activities. Limited engagement in pulmonary... Read more
Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more
Health IT
view channel
AI System Detects and Quantifies Chronic Subdural Hematoma
Viz.ai (San Francisco, CA, USA) announced a strategic commercialization collaboration with Johnson & Johnson (New Brunswick, NJ, USA) to expand access in the United States to the Viz Subdural solution... Read more
Continuous Monitoring Platform Detects Infection Risk Across Care Transitions
Patients leaving skilled nursing facilities often lose continuous physiologic monitoring, increasing the risk of undetected infection and delayed intervention. Nursing home residents are seven times more... Read more
Automated System Classifies and Tracks Cardiogenic Shock Across Hospital Settings
Cardiogenic shock remains a difficult, time-sensitive emergency, with delayed identification driving poor outcomes and persistently high mortality. Many cases go undocumented even at advanced stages, hindering... Read more
Point of Care
view channel
Business
view channel
Johnson & Johnson Launches AI-Driven Cardiac Mapping System
Johnson & Johnson has introduced the CARTOSOUND SONATA Module for the CARTO System at the Heart Rhythm Society (HRS) 2026 meeting in Chicago. The module uses artificial intelligence with the CARTO... Read more
